Top

Published in:

01-08-2017 | Original Article

A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Authors: T. Hasegawa, A. Kawakita, N. Ueda, R. Funahara, A. Tachibana, M. Kobayashi, E. Kondou, D. Takeda, Y. Kojima, S. Sato, S. Yanamoto, H. Komatsubara, M. Umeda, T. Kirita, H. Kurita, Y. Shibuya, T. Komori, Japanese Study Group of Cooperative Dentistry with Medicine (JCDM)

Published in: Osteoporosis International | Issue 8/2017

Abstract

Summary

Root amputation, extraction of a single tooth, bone loss or severe tooth mobility, and an unclosed wound were significantly associated with increased risk of developing medication-related osteonecrosis of the jaw (MRONJ). We recommend a minimally traumatic extraction technique, removal of any bone edges, and mucosal wound closure as standard procedures in patients receiving bisphosphonates.

Introduction

Osteonecrosis of the jaws can occur following tooth extraction in patients receiving bisphosphonate drugs. Various strategies for minimizing the risk of MRONJ have been advanced, but no studies have comprehensively analyzed the efficacy of factors such as primary wound closure, demographics, and drug holidays in reducing its incidence. The purpose of this study was to retrospectively investigate the relationships between these various risk factors after tooth extraction in patients receiving oral bisphosphonate therapy.

Methods

Risk factors for MRONJ after tooth extraction were evaluated using univariate and multivariate analysis. All patients were investigated with regard to demographics; type and duration of oral bisphosphonate use; whether they underwent a discontinuation of oral bisphosphonates before tooth extraction (drug holiday), and the duration of such discontinuation; and whether any additional surgical procedures (e.g., incision, removal of bone edges, root amputation) were performed.

Results

We found that root amputation (OR = 6.64), extraction of a single tooth (OR = 3.70), bone loss or severe tooth mobility (OR = 3.60), and an unclosed wound (OR = 2.51) were significantly associated with increased risk of developing MRONJ.

Conclusions

We recommend a minimally traumatic extraction technique, removal of any bone edges, and mucosal wound closure as standard procedures in patients receiving bisphosphonates. We find no evidence supporting the efficacy of a pre-extraction short-term drug holiday from oral bisphosphonates in reducing the risk of MRONJ.

Kanis JA, Gertz BJ, Singer F, Ortolani S (1995) Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5:1–13CrossRefPubMed

Rogers MJ, Watts DJ, Russell RG (1997) Overview of bisphosphonates. Cancer 80:1652–1660CrossRefPubMed

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed

Russell RG, Xia Z, Dunford JE et al (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257CrossRefPubMed

Açil Y, Möller B, Niehoff P, Rachko K, Gassling V, Wiltfang J, Simon MJ (2012) The cytotoxic effects of three different bisphosphonates in vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg 40:e229–e235CrossRefPubMed

Ziebart T, Pabst A, Klein MO et al (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105–111CrossRefPubMed

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860CrossRefPubMed

Roelofs AJ, Coxon FP, Ebetino FH et al (2010) Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25:606–616CrossRefPubMed

Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847CrossRefPubMedPubMedCentral

10.

Filleul O, Crompot E, Saussez S (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 136:1117–1124CrossRefPubMed

11.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956CrossRefPubMed

12.

Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–423CrossRefPubMed

13.

Kunchur R, Need A, Hughes T et al (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167CrossRefPubMed

14.

Damm DD, Jones DM (2013) Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 61:33PubMed

15.

Hellstein JW, Adler RA, Edwards B et al (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243–1251CrossRefPubMed

16.

Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23CrossRefPubMed

17.

Mozzati M, Arata V, Gallesio G, Carossa S (2011) Tooth extraction and oral bisphosphonates: comparison of different surgical protocols. Joint Bone Spine 78:647–654CrossRefPubMed

18.

Mozzati M, Arata V, Gallesio G (2013) Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos Int 24:1707–1712CrossRefPubMed

19.

Malden N, Beltes C, Lopes V (2009) Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 206:93–98CrossRefPubMed

20.

Ferlito S, Liardo C, Puzzo S (2010) Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Minerva Stomatol 59:593–601PubMed

21.

Ferlito S, Puzzo S, Liardo C (2011) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69:e1–e4CrossRefPubMed

22.

Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, Ferronato G, Nocini PF, Bedogni A (2010) Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 68:797–804CrossRefPubMed

23.

Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefPubMed

24.

Vescovi P, Campisi G, Fusco V et al (2011) Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 47:191–194CrossRefPubMed

25.

Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:1631–1637CrossRefPubMed

26.

Yoneda T, Hagino H, Sugimoto T et al (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365–383CrossRefPubMed

27.

Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836CrossRefPubMed

28.

Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932CrossRefPubMed

29.

Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259–1269CrossRefPubMed

30.

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB (2009) Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 14:181–191CrossRefPubMed

31.

Migliorati CA (2003) Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254CrossRefPubMed

32.

Hasegawa T, Ri S, Umeda M, Komatsubara H, Kobayashi M, Shigeta T, Yoshitomi I, Ikeda H, Shibuya Y, Asahina I, Komori T (2013) The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. J Craniomaxillofac Surg 41:558–563CrossRefPubMed

33.

Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613–1620CrossRefPubMedPubMedCentral

34.

Otto S, Baumann S, Ehrenfeld M, Pautke C (2013) Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. J Craniomaxillofac Surg 41:694–698CrossRefPubMed

35.

Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed

36.

Migliorati CA, Saunders D, Conlon MS et al (2013) Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction. J Am Dent Assoc 144:406–414CrossRefPubMed

37.

Heufelder MJ, Hendricks J, Remmerbach T, Frerich B, Hemprich A, Wilde F (2014) Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 117:e429–e435CrossRefPubMed

38.

Aguirre JI, Akhter MP, Kimmel DB et al (2012) Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res 27:2130–2143CrossRefPubMedPubMedCentral

39.

Dayisoylu EH, Ungor C, Tosun E et al (2014) Does an alkaline environment prevent the development of bisphosphonate-related osteonecrosis of the jaw? An experimental study in rats. Oral Surg Oral Med Oral Pathol Oral Radiol 117:329–334CrossRefPubMed

40.

Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43:847–854CrossRefPubMed

41.

Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35–41CrossRefPubMed

42.

Otto S, Pautke C, Opelz C et al (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845CrossRefPubMed

43.

Katsarelis H, Shah NP, Dhariwal DK, Pazianas M (2015) Infection and medication-related osteonecrosis of the jaw. J Dent Res 94:534–539CrossRefPubMed

44.

Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 103:232–240CrossRefPubMed

45.

Bodem JP, Kargus S, Eckstein S, Saure D, Engel M, Hoffmann J, Freudlsperger C (2015) Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction. J Craniomaxillofac Surg 43:510–514CrossRefPubMed

Title: A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Authors: T. Hasegawa
A. Kawakita
N. Ueda
R. Funahara
A. Tachibana
M. Kobayashi
E. Kondou
D. Takeda
Y. Kojima
S. Sato
S. Yanamoto
H. Komatsubara
M. Umeda
T. Kirita
H. Kurita
Y. Shibuya
T. Komori
Japanese Study Group of Cooperative Dentistry with Medicine (JCDM)
Publication date: 01-08-2017
Publisher: Springer London
Published in: Osteoporosis International / Issue 8/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4063-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2017

A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women

Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study

Mutational and biochemical findings in adults with persistent hypophosphatasemia

Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site

Sex-related variations in cortical and trabecular bone of the femoral neck in an elderly Chinese population

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?